arrow
J

Jan Basile

Medical University of South Carolina
H指数:44
被引数:1.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Changes in Metabolic and Blood Pressure Outcomes With Semaglutide Across Chronic Kidney Disease Stages: A Post Hoc Analysis of the FLOW Trial

使用司美格鲁肽治疗时,不同慢性肾病分期患者的代谢和血压结局变化:<scp>FLOW</scp>试验的事后分析

2026-11-030
OAAI
Patient-Level Pooled Analysis of Endovascular Ultrasound Renal Denervation or a Sham Procedure 6 Months After Medication Escalation: The RADIANCE Clinical Trial Program
2024-03-0513
PRE
Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics
2024-01-0179
OAAI
Patient-Level Pooled Analysis of Ultrasound Renal Denervation in the Sham-Controlled RADIANCE II, RADIANCE-HTN SOLO, and RADIANCE-HTN TRIO Trials
2023-05-0147
OAAI
Endovascular Ultrasound Renal Denervation to Treat Hypertension: The RADIANCE II Randomized Clinical Trial
2023-02-2891
OA
Effects of Renal Denervation vs Sham in Resistant Hypertension After Medication Escalation Prespecified Analysis at 6 Months of the RADIANCE-HTN TRIO Randomized Clinical Trial
2022-12-0127
OAAI
Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post-hoc analysis from the REWIND randomized trial

杜拉鲁肽与有和没有心力衰竭的患者的心血管和心力衰竭结局: 来自REWIND随机试验的事后分析

2022-09-2017
PRE
A novel kidney disease index reflecting both the albumin-to-creatinine ratio and estimated glomerular filtration rate, predicted cardiovascular and kidney outcomes in type 2 diabetes
2022-08-2210
OAAI
Novel Indices of Cognitive Impairment and Incident Cardiovascular Outcomes in the REWIND Trial
2022-04-213
OA
Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes: A post hoc analysis from the REWIND randomized trial
2022-01-248
PRE
Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial
LANCET
IF88.5
2021-06-01225
OAAI
12-Month Results From the Unblinded Phase of the RADIANCE-HTN SOLO Trial of Ultrasound Renal Denervation
2020-12-0147
OAAI